,
~
1
٨
7
$\mathcal{C}_{\mathcal{L}}$
7/1
v

Notice of Allowability

Application No.	Applicant(s)	_		
09/487,979	SKURKOVICH ET AL.	SKURKOVICH ET AL.		
Examiner	Art Unit	_		
Phillip Gambel	1644			

riones of rinomasiney	Examiner	Art Unit		
	Phillip Gambel	1644		
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apply or other appropriate communication IGHTS. This application is subject to	olication. If not include will be mailed in due	ed course. THIS	
1. This communication is responsive to 4/26/64				
2. 「The allowed claim(s) is/are 42,46 たんったら	na) 1-2.			
3. The drawings filed on are accepted by the Examine	r.			
 4. Acknowledgment is made of a claim for foreign priority unally All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE"	e been received. e been received in Application No cuments have been received in this of this communication to file a reply	national stage applica		
noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be subminformal PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINER	'S AMENDMENT or N	OTICE OF	
6. CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner' Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in to 7. DEPOSIT OF and/or INFORMATION about the deponant attached Examiner's comment regarding REQUIREMENT	st be submitted. son's Patent Drawing Review (PTO s Amendment / Comment or in the C .84(c)) should be written on the drawin the header according to 37 CFR 1.121(c) sit of BIOLOGICAL MATERIAL n	948) attached Office action of the front (not the d). nust be submitted. I	·	
Add a large and ()				
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application (PT	O-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)		6. ☐ Interview Summary (PTO-413), Paper No./Mail Date 7. ☑ Examiner's Amendment/Comment		
 Information Disclosure Statements (PTO-1449 or PTO/SB/C Paper No./Mail Date 				
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ☑ Examiner's Stateme 9. ☐ Other	PHILLIP GAN Phillip Gambel Primary Examiner Art Unit: 1644 TRH CEUTH	NBEC 7/22/04	

Art Unit: 1644

DETAILED ACTION

1. Applicant's amendment, filed 4/26/04, has been entered. Claim 46 has been amended.

Claims 1-41, 43-44 and 47 have been canceled previously. Claims 42, 45, 46 and 48-50 are pending.

2. Applicant is reminded that the Listing of the Claims is not a complete listing of all of the claims. Additionally, each claims also not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. For further explanation of the amendment format required by 37 CFR § 1.121, see MPEP § 714.

EXAMINER'S AMENDMENT

- 3. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.
- 4. Claims 45 and 48-50, drawn to nonelected claims, have been canceled.
- 5. The title has been replaced with the following:
- -- TREATMENT OF AIDS WITH ANTIBODIES TO GAMMA INTERFERON, ALPHA INTERFERON AND TNF-ALPHA -- .

LISTING OF CLAIMS

6. The following is a complete list of the claims.

Claims 1-41. (Canceled).

Claim 42. (Previously Presented). A method of treating Acquired Immunodeficiency Disease in a patient comprising administering to said patient an effective amount of a combination of an antibody to gamma interferon, an antibody to alpha interferon, and an antibody to tumor necrosis factor-alpha.

Claims 43-45. (Canceled.)

Claim 46. (Previously Presented) The method of claim 42, wherein said antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, combinations thereof, and a biologically active fragment wherein the biologically active fragment is a fragment of an antibody and binds gamma interferon, alpha interferon or tumor necrosis factor alpha.

Claims 48-50. (Canceled)

Art Unit: 1644

REASONS FOR ALLOWANCE

7. The following is an Examiner's Statement of Reasons for Allowance:

Upon reconsideration of applicant's amended claims, filed 4/26/04; the previous rejections under 35 USC 112, first and second paragraphs have been withdrawn. In addition, upon reconsideration of applicant's arguments, particularly with respect to the disclosure of Skurkovich (Medical Hypothesis 42: 27-35, 1994, particularly page 31, paragraph 2) that the administration of antibodies to interferons is impractical; the previous rejections under 35 USC 103(a) has been withdrawn. Accordingly, the instant claims are deemed allowable.

- 8. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Plence GAMBE

Phillip Gambel, Ph.D.

Primary Examiner

Technology Center 1600

July 23, 2004